The looming study of B is looking like a short term and inexpensive one. Even without significant new CTIX financing, if we get some cooperative medical institution (they should be easy to find, given Dr. M's and Leo's connections) to do the study if CTIX just provides the drug. This would be similar to MD Anderson's and U of Bologna's deals for the next studies of K. The institutions get the prestige of being pioneers; CTIX gets the study done inexpensively. The world gets new needed antibiotic quickly: WIN, WIN, WIN.
News 
Market Data 
Discover 
AI
